NCT00742924: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma |
|
|
| Completed | 1 | 24 | US, Canada, RoW | cisplatin, Cis-diamminedichloroplatinum II, CDDP, cis-DDP, Platinol-AQ, NSC #119875, dexrazoxane hydrochloride, ICRF-187, ADR-529, ZINECARD, NSC #169780, doxorubicin hydrochloride, Adriamycin, NSC #123127, etoposide, VePesid, Etopophos, VP-16, NSC #141540, ifosfamide, Isophosphamide, Iphosphamide, Z4942, Ifex, NSC #109724, leucovorin calcium, LCV, Wellcovorin, citrovorum factor, folinic acid, NSC #003590, methotrexate, MTX, amethopterin, Trexall, NSC #000740, zoledronic acid, 1-Hydroxy-2-imidazol-1-ylethylidene - diphosphonic acid, zoledronate, Zometa, Aclasta, NSC# 721517, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Granulocyte Colony-Stimulating Factor, r-metHuG-CSF, G-CSF, Neupogen, NSC #614629, Mesna, sodium 2-mercaptoethane sulfonate, UCB 3983, Mesnex, NSC #113891 | Children's Oncology Group, National Cancer Institute (NCI) | Sarcoma | 04/12 | | | |
